P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE

• Takahiro Kumode,
• Wataru Munakata,
• Hideki Goto,
• Noriko Fukuhara,
• Tatsu Shimoyama,
• Masahiro Takeuchi,
• Toshiro Kawakita,
• Kohmei Kubo,
• Masashi Sawa,
• Toshiki Uchida,
• Yuko Mishima,
• Michiko Ichii,
• Miyoko Hanaya,
• Asuka Matsumoto,
• Masaaki Kuriki,
• Koji Izutsu,
• Kenichi Ishizawa

Affiliations

Takahiro Kumode

1 Kindai University Fuculty of Medicine, Osaka-Sayama, Japan

Wataru Munakata

2 National Cancer Center Hospital, Tokyo, Japan

Hideki Goto

3 Hokkaido University Hospital, Sapporo, Japan

Noriko Fukuhara

4 Tohoku University Hospital, Sendai, Japan

Tatsu Shimoyama

5 Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan

Masahiro Takeuchi

6 Chiba Cancer center, Chiba, Japan

Toshiro Kawakita

7 National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan

Kohmei Kubo

8 Aomori Prefectural Central Hospital, Aomori, Japan

Masashi Sawa

9 Anjo Kosei Hospital, Anjo, Japan

Toshiki Uchida

10 Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan

Yuko Mishima

11 The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

Michiko Ichii

12 Osaka University Hospital, Suita, Japan

Miyoko Hanaya

13 Kyowa Kirin Co., Ltd, Tokyo, Japan

Asuka Matsumoto

13 Kyowa Kirin Co., Ltd, Tokyo, Japan

Masaaki Kuriki

13 Kyowa Kirin Co., Ltd, Tokyo, Japan

Koji Izutsu

2 National Cancer Center Hospital, Tokyo, Japan

Kenichi Ishizawa

14 Yamagata University Faculty of Medicine, Yamagata, Japan